Will fluoroquinolones ever be recommended for common infections in children?

Pediatric Infectious Disease Journal

Volumn 26, Issue 10, 2007, Pages 865-867

  Schaad, Urs B ^a  

^a UNIVERSITY CHILDREN S HOSPITAL   (Switzerland)

Author keywords

[No Author keywords available]

Indexed keywords

ANTIBIOTIC AGENT; LEVOFLOXACIN; MITOCHONDRIAL DNA; QUINOLONE DERIVATIVE;

ANTIBIOTIC RESISTANCE; ANTIBIOTIC THERAPY; ARTHRITIS; ARTHROPATHY; BACTERIAL INFECTION; CHEMICAL STRUCTURE; CLINICAL EXAMINATION; CLINICAL TRIAL; COMMUNITY ACQUIRED PNEUMONIA; CYSTIC FIBROSIS; DRUG EFFICACY; DRUG SAFETY; ECHOGRAPHY; EXPERIENCE; HISTOPATHOLOGY; HUMAN; JUVENILE ANIMAL; KNOWLEDGE; MITOCHONDRIAL DNA REPLICATION; NONHUMAN; NUCLEAR MAGNETIC RESONANCE IMAGING; PEDIATRICS; PRACTICE GUIDELINE; PRIORITY JOURNAL; REVIEW; STREPTOCOCCUS PNEUMONIAE; URINARY TRACT INFECTION;

EID: 34848853611     PISSN: 08913668     EISSN: None     Source Type: Journal    
DOI: 10.1097/INF.0b013e3180cc20e4     Document Type: Article

References (23)

1. Bradley JS, Arguedas A, Blumer JL, et al. Comparative study of levofloxacin in the treatment of children with community-acquired pneumonia. Pediatric Infect Dis J. 2007;26:868-878.
2. Noel GJ, Bradley JS, Kauffman RE, et al. Comparative safety profile of levofloxacin in 2523 children with a focus on four specific musculoskeletal disorders. Pediatric Infect Dis J. 2007;26:879-891.
3. Stahlmann R, Lode H. Safety overview: toxicity, adverse effects, and drug interactions. In: Andriole VT, ed. The Quinolones. San Diego: Academic Press, 2000;398-453.
4. Gough A, Barsoum NJ, Mitchell L, et al. Juvenile canine drug-induced arthropathy: clinicopathological studies on articular lesions caused by oxolinic and pipemidic acids. Toxicol Appl Pharmacol. 1979;51:177-187.
5. Christ W, Lehnert T, Ulbrich B. Specific toxicologic aspects of the quinolones. Rev Infect Dis. 1988;10(suppl 1):141-146.
6. Schluter G. Ciprofloxacin: Toxicologic evaluation of additional safety data. Am J Med. 1989;87(suppl 5A):37-39.
7. Schaad UB, Salam MA, Aujard Y, et al. Use of fluoroquinolones in pediatrics: consensus report of an International Society of Chemotherapy commission. Pediatr Infect Dis J. 1995;14:1-9.
8. Schaad UB. Use of the quinolones in pediatrics. In: Andriole VT, ed. The Quinolones. San Diego: Academic Press, 2000;455-475.
9. Kato M, Takada S, Ogawara S, et al. Effect of levofloxacin on glycosaminoglycan and DNA synthesis of cultured rabbit chondrocytes at concentrations inducing cartilage lesions in vivo. Antimicrob Agents Chemother. 1995;39:1979-1983.
10. Vormann J, Forster C, Zippel U, et al. Effects of magnesium deficiency on magnesium calcium content in bone and cartilage in developing rats in correlation to chondrotoxicity. Calcif Tissue Int. 1997;61:230-238.
11. Schaad UB, Sander E, Wedgwood J, et al. Morphologic studies for skeletal toxicity after prolonged ciprofloxacin therapy in two juvenile cystic fibrosis patients. Pediatr Infect Dis J. 1992;11:1047-1049.
12. Schaad UB, Stoupis C, Wedgwood J, et al. Clinical, radiologic and magnetic resonance monitoring for skeletal toxicity in pediatric patients with cystic fibrosis receiving a three-month course of ciprofloxacin. Pediatr Infect Dis J. 1991;10:723-729.
13. Richard DA, Nousia-Arvanitakis S, Sollich V, et al. Oral ciprofloxacin versus intravenous ceftazidime plus tobramycin in pediatric cystic fibrosis patients: Comparison of antipseudomonas efficacy and assessment of safety using ultrasonography and magnetic resonance imaging. Pediatr Infect Dis J. 1997;16:572-578.
14. Church DA, Kanga JF, Kuhn RF, et al. Sequential ciprofloxacin therapy in pediatric cystic fibrosis: comparative study vs. ceftazidime/tobramycin in the treatment of acute pulmonary exacerbations. Pediatr Infect Dis J. 1997;16:97-105.
15. Pradhan KM, Arora NK, Jena A, et al. Safety of ciprofloxacin therapy in children: magnetic resonance images, body fluid levels of fluoride and linear growth. Acta Paediatr. 1995;84:555-560.
16. Burkhardt JE, Walterspiel JN, Schaad UB. Quinolone arthropathy in animals versus children. Clin Infect Dis. 1997;25:1196-1204.
17. Schaad UB. Fluoroquinolone antibiotics in infants and children. Infect Dis Clin N Am. 2005;19:617-628.
18. Phillips BB, David T. Pathogenesis and management of arthropathy in cystic fibrosis. J Roy Soc Med. 1996;79(suppl 12):44-50.
19. Mandell LA, Peterson LR, Wise R, et al. The battle against emerging antibiotic resistance: should fluoroquinolones be used to treat children? Clin Infect Dis. 2002;35:721-727.
20. Hooper DC. New uses for new and old quinolones and the challenge of resistance. Clin Infect Dis. 2000;30:243-254.
21. Gendrel D, Chalumeau M, Moulin F, et al. Fluoroquinolones in paediatrics: a risk for the patient or for the community? Lancet Infect Dis. 2003;3:537-546.
22. Kronenberger CB, Hoffmann RE, Lezotte DC. Invasive penicillin-resitant pneumococcal infections: a prevalence and historical cohort study. Emerg Infect Dis. 1996;2:121-124.
23. Dagan R, Arguedas A, Schaad UB. Potential role of fluoroquinolone therapy in childhood otitis media. Pediatr Infect Dis J. 2004;23:390-398.